{"database":"ecrin-mdr-crc","file_versions":[],"scores":null,"additional":{"omics_type":["Clinical"],"study_start_year":["2014"],"condition":["KRAS and NRAS Wild-type Colorectal Cancer","Colorectal Neoplasms"],"disease":["Colorectal Neoplasms","Kras And Nras Wild-type Colorectal Cancer"],"study_type":["Interventional"],"full_dataset_link":["https://newmdr.ecrin.org/Study/2171254"],"location":["United States"],"study_start_month":["6"],"keyword":["Panitumumab"],"repository":["ECRIN MDR"],"study_status":["Terminated"],"additional_accession":[]},"is_claimable":false,"name":"Regorafenib + Panitumumab for Colorectal Cancers","description":"Evaluate the safety of regorafenib and panitumumab","dates":{"creation":"2014-06-15"},"accession":"2171254","cross_references":{"ClinicalTrials___gov":["NCT02199223"]}}